Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058838 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT00058838: Completed Phase 3 study, sponsored by Pfizer.
NCT00058838 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 854 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058838, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
Interventions
- DRUG sumanirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
What the finished NCT00058838 record still lists
NCT00058838 is an interventional study that assigns participants to a tested intervention. The registered 854 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 1 intervention - of which sumanirole is the first listed.
NCT00058838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00058838 about?
NCT00058838 is a clinical study titled "Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease". The primary purpose of this study is to determine whether sumanirole, at three different dose levels, is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease
What is the current status of trial NCT00058838?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2003-04. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00058838?
The interventions under investigation include: sumanirole (DRUG).
Who is sponsoring clinical trial NCT00058838?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00058838's enrollment target sits among peer trials
854 384th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia